• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on: Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.

作者信息

Călugăru Dan, Călugăru Mihai

机构信息

Department of Ophthalmology, University of Medicine Cluj-Napoca 400014, Romania.

出版信息

Int J Ophthalmol. 2022 Apr 18;15(4):681-682. doi: 10.18240/ijo.2022.04.27. eCollection 2022.

DOI:10.18240/ijo.2022.04.27
PMID:35450193
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8995729/
Abstract
摘要

相似文献

1
Comment on: Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.关于《康柏西普治疗糖尿病性黄斑水肿两年的真实世界研究结果》的评论
Int J Ophthalmol. 2022 Apr 18;15(4):681-682. doi: 10.18240/ijo.2022.04.27. eCollection 2022.
2
Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model.康柏西普与雷珠单抗治疗年龄相关性黄斑变性、糖尿病性黄斑水肿和病理性近视的成本效益：基于人群的队列研究和马尔可夫模型
Front Med (Lausanne). 2021 Dec 2;8:750132. doi: 10.3389/fmed.2021.750132. eCollection 2021.
3
One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema.康柏西普治疗糖尿病性黄斑水肿的一年疗效
Curr Eye Res. 2018 Feb;43(2):218-223. doi: 10.1080/02713683.2017.1379542. Epub 2017 Dec 21.
4
Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study.康柏西普与雷珠单抗治疗糖尿病性黄斑水肿12个月的疗效比较：一项真实世界临床实践研究
BMC Ophthalmol. 2017 Aug 25;17(1):158. doi: 10.1186/s12886-017-0554-8.
5
One-year outcomes of novel VEGF decoy receptor therapy with intravitreal conbercept in diabetic retinopathy-induced macular edema.玻璃体内注射康柏西普新型VEGF诱饵受体疗法治疗糖尿病性视网膜病变引起的黄斑水肿的一年疗效
Mol Vis. 2019 Oct 21;25:636-644. eCollection 2019.
6
Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.康柏西普治疗糖尿病性黄斑水肿两年的真实世界疗效
Int J Ophthalmol. 2021 Mar 18;14(3):416-422. doi: 10.18240/ijo.2021.03.14. eCollection 2021.
7
[Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].[基于光学相干断层扫描分类的不同类型糖尿病性黄斑水肿对康柏西普的治疗反应]
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Oct 20;41(10):1501-1508. doi: 10.12122/j.issn.1673-4254.2021.10.08.
8
Microvascular Changes After Conbercept Intravitreal Injection of PDR With or Without Center-Involved Diabetic Macular Edema Analyzed by OCTA.通过光学相干断层扫描血管造影（OCTA）分析康柏西普玻璃体腔注射治疗增殖性糖尿病视网膜病变伴或不伴累及黄斑中心的糖尿病性黄斑水肿后的微血管变化。
Front Med (Lausanne). 2022 Mar 22;9:797087. doi: 10.3389/fmed.2022.797087. eCollection 2022.
9
Correlation of retinal layer changes with vision gain in diabetic macular edema during conbercept treatment.康柏西普治疗糖尿病性黄斑水肿期间视网膜层变化与视力改善的相关性
BMC Ophthalmol. 2019 May 31;19(1):123. doi: 10.1186/s12886-019-1131-0.
10
Comparison of conbercept and ranibizumab for the treatment efficacy of diabetic macular edema: a Meta-analysis and systematic review.康柏西普与雷珠单抗治疗糖尿病性黄斑水肿疗效的比较：一项Meta分析与系统评价
Int J Ophthalmol. 2019 Sep 18;12(9):1479-1486. doi: 10.18240/ijo.2019.09.17. eCollection 2019.

引用本文的文献

1
Effect of aflibercept combined with triamcinolone acetonide on aqueous humor growth factor and inflammatory mediators in diabetic macular edema.阿柏西普联合曲安奈德对糖尿病性黄斑水肿房水生长因子及炎症介质的影响
Int J Ophthalmol. 2024 Feb 18;17(2):297-303. doi: 10.18240/ijo.2024.02.11. eCollection 2024.

本文引用的文献

1
Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.康柏西普治疗糖尿病性黄斑水肿两年的真实世界疗效
Int J Ophthalmol. 2021 Mar 18;14(3):416-422. doi: 10.18240/ijo.2021.03.14. eCollection 2021.
2
Classifications of diabetic macular edema.糖尿病性黄斑水肿的分类
Eur J Ophthalmol. 2020 Jan;30(1):6-7. doi: 10.1177/1120672119889532. Epub 2019 Nov 26.
3
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 Phoenix Study.康柏西普治疗新生血管性年龄相关性黄斑变性：3期随机凤凰研究结果
Am J Ophthalmol. 2019 Feb;198:262-263. doi: 10.1016/j.ajo.2018.09.027. Epub 2018 Nov 3.
4
Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.玻璃体内注射抗血管内皮生长因子疗法治疗年龄相关性黄斑变性后脉络膜厚度的变化：雷珠单抗与阿柏西普对比
J Ocul Pharmacol Ther. 2015 Jul-Aug;31(6):357-62. doi: 10.1089/jop.2014.0160. Epub 2015 Jun 3.
5
TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.视网膜疾病中抗血管内皮生长因子（VEGF）药物的治疗与延长方案：文献综述与共识建议
Retina. 2015 Aug;35(8):1489-506. doi: 10.1097/IAE.0000000000000627.
6
Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy.玻璃体内注射贝伐单抗和经Tenon 囊曲安奈德注射联合防治光动力疗法诱导脉络膜毛细血管闭塞的保护作用。
Ophthalmologica. 2010;224(5):267-73. doi: 10.1159/000287348. Epub 2010 Feb 25.